A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas. The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials. Primary objectives of the different sub-studies : * phase 1 sub-studies: determine the safety and tolerability of escalating doses of the sub-study treatment * phase 2 sub-studies: identify drugs that will improve significantly the outcome in target patients Secondary objectives of both sub-studies: analyze the response rate, the clinical benefit rate, the progression-free survival, the duration of response, the time to next treatment or death, the overall survival, the rate of transplantation following study treatment and the safety profile of the drugs used

NCT Number	NCT07018752
Lead Sponsor	The Lymphoma Academic Research Organisation Collaborators: iOnctura, AbbVie, Bristol-Myers Squibb
Conditions	Peripheral T Cells Lymphoma (PTCL)
Enrollment	49 participants
Start Date	2025-08-20
Primary Completion	2028-04 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-11